Helix Biopharma Corp. to present at 3rd Annual Immuno-Oncology BDL and Investment Forum

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that company Chief Executive Officer and Chief Science Officer, Heman Chao, will be presenting at the upcoming 3rd Annual Immuno-oncology BD&L and Investment Forum (“IOBD&L”) taking place on June 2nd, 2017 at the Hyatt Chicago Magnificent Mile Hotel.